Consensus EPS · Q3 2026
$3.05
Consensus revenue · Q3 2026
$25.3B
Analysts
11
Expected report
Oct 13, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 11 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $25B | $25.3B | $25.6B |
| EPS | $2.95 | $3.05 | $3.18 |
| EBITDA | $8.4B | $8.4B | $8.5B |
| EBIT | $6.2B | $6.2B | $6.3B |
| Net income | $7.2B | $7.4B | $7.7B |
- Revenue$25.3B
- EPS$3.05
- EBITDA$8.4B
- EBIT$6.2B
- Net income$7.4B
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q2 2026 | $25.3B | $25.1B | +1.0% | $2.90 | $2.85 | +1.6% |
| Q1 2026 | $24.1B | $23.6B | +1.9% | $2.70 | $2.68 | +0.8% |
| Q4 2025 | $24.6B | $24.1B | +1.7% | $2.46 | $2.46 | -0.1% |
- Q2 2026+1.0%+1.6%
- Q1 2026+1.9%+0.8%
- Q4 2025+1.7%-0.1%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Johnson & Johnson (JNJ) Q3 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 13 analysts.
- Low
- $220.00
- Consensus
- $272.69
- Median
- $272.00
- High
- $305.00
- Current
- $255.63
- Upside
- +6.7%
Upside calculated vs most recent trading price of $255.63.
Analyst ratings
Consensus: Buy — based on 40 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 17, 2026 | Guggenheim | maintain | Buy | Buy |
| Jul 16, 2026 | Wells Fargo | maintain | Overweight | Overweight |
| Jul 16, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jul 16, 2026 | Raymond James | maintain | Outperform | Outperform |
| Jul 16, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 13, 2026 | TD Cowen | maintain | Buy | Buy |
| Jul 13, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Jul 10, 2026 | B of A Securities | maintain | Neutral | Neutral |
| Jul 8, 2026 | Morgan Stanley | maintain | Overweight | Overweight |
| Jul 8, 2026 | Citigroup | maintain | Buy | Buy |
- Jul 17, 2026GuggenheimBuy
- Jul 16, 2026Wells FargoOverweight
- Jul 16, 2026RBC CapitalOutperform
- Jul 16, 2026Raymond JamesOutperform
- Jul 16, 2026Morgan StanleyOverweight
- Jul 13, 2026TD CowenBuy
- Jul 13, 2026RBC CapitalOutperform
- Jul 10, 2026B of A SecuritiesNeutral
- Jul 8, 2026Morgan StanleyOverweight
- Jul 8, 2026CitigroupBuy
Frequently asked questions
Johnson & Johnson (JNJ) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks1.32% TTM
- Dividend Profile2.05% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History7 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.